新萊福(301323.SZ):醫用散射射線防護毯作為醫用耗材已成功納入某海外國家醫保目錄範圍
格隆匯11月21日丨新萊福(301323.SZ)於近期投資者關係活動表示,2024年前三季度,高能射線無鉛防護材料延續了自2023年以來的強勁增長趨勢,繼續呈現出高速增長的良好態勢。醫用散射射線防護毯作為醫用耗材已成功納入某海外國家醫保目錄範圍,這為該產品在國際市場進一步拓展奠定了堅實基礎,也充分彰顯了其在醫用射線防護領域的卓越品質與廣泛認可度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.